Bluebird raising $211M; Alimera inks $50M financing deal;

@FierceBiotech: Cyclacel's cancer drug isn't working in Phase III, but that won't stop the trial. Story | Follow @FierceBiotech

@JohnCFierce: Top Monday story: UPDATED: Onyx vet Tony Coles embarks on a new biotech adventure. More | Follow @JohnCFierce

@DamianFierce: Scathing new ad for tightening regs on private equity. Story | Follow @DamianFierce

> Cambridge, MA-based bluebird bio ($BLUE) is raising $211 million through the sale of 2.6 million shares. Release

> Atlanta-based Alimera Sciences inked a $50 million financing deal with Deerfield. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: FDA clears laser-based comb to combat hair loss. Article | Follow @FierceMedDev

@StacyALawrence: GE-backed InSightec gets $59M for noninvasive surgical tool, adds ex-Mako CEO to board. More | Follow @StacyALawrence

@EmilyWFierce: Power morcellator fallout illustrates major flaw in FDA's device regulation. WSJ story | Follow @EmilyWFierce

> Fresenius adds blood purification tech to its dialysis offerings via partnership. Article

> FDA took a back seat in morcellator regulation, researchers say. Report

Pharma News

@FiercePharma: New chief picks team to fuse Actavis with Allergan. Article | Follow @FiercePharma

@EricPFierce: ICYMI: Third round of cuts slated for Novartis US Diovan plant. Total reaches 133 with 394 more gone by 2016. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Baxter backs away from vaccines with Vero tech sale to Nanotherapeutics. More | Follow @CarlyHFierce

> Roche's Lucentis nabs FDA 'breakthrough' tag for diabetic eye disease. More

> FTC plows ahead in pay-for-delay suit over AbbVie's AndroGel. Article

> Fresh off Afinitor failure, Novartis turns tide with Signifor LAR approval. News

Pharma Manufacturing News

> Biocon to build new plant in Vizag, India. Report

> Industry Voices: The future of pharma manufacturing--new disruptive technologies that can impact whole industry structures. More

> Baxter has yet another recall of sodium chloride. News

> Teva continues to whittle down manufacturing network. Story

> Avid Bioservices doubling capacity at its California facility. Article

Biotech Research News

> Scientists look to a pathway in the gut to fix fatty liver disease. Piece

> Repurposed fibroblasts may open the door to new melanoma drugs, screening tech. More

> Investigators hit on a new class of stem cells. Item

> Joslin investigators urge cosmetics groups to get into anti-aging R&D. Article

> NIH's children's health study ends as a $1.2B disaster. Story

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.